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Plasmodium falciparum malaria is one of the most important parasitic diseases affecting sub-Saharan 
Africa, despite the availability of interventions. It exerts tremendous socio-economic and medical 
burden on the continent, particularly in under five children and pregnant women. In this review, we have 
attempted to highlight the problems, constraints and the opportunities that are available for effective 
prevention and control within the region. 
 





Malaria is a febrile illness characterized by fever and 
related symptoms. It has been one of the most prevalent 
human diseases affecting particularly the populations of 
tropical regions and in the past those of temperate 
climates (Bruce-Chwatt, 1986). Malaria is a complex 
disease that varies in epidemiology and clinical 
manifestation in different parts of the world. This 
variability occurs as a result of several factors such as: 
the species of malaria parasites that are found in a given 
area, the distribution and efficiency of mosquito vectors, 
climate and other environmental conditions, the 
susceptibility of malarial parasites to commonly used or 
available antimalarial drugs and the level of acquired 
immunity by the exposed human population (Bloland, 
2001). Of the four common species of Plasmodium 
responsible for malaria in endemic regions of the world, 
Plasmodium falciparum is the most virulent (Bruce-
Chwatt, 1986). It is responsible for over 90% of all 
causes of malaria in sub-Saharan Africa (WHO, 2000). 
In Africa, as in other parts of the world, the malaria 
situation is not homogenous. In spite of its wide 
distribution in the continent, it is actually a focal disease. 
It varies from country to country and in the same country,  
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it may vary from one part to another (FMoH, 2000). 
Therefore, the distribution of malaria in Africa may be 
classified broadly into four epidemiological areas - the 
hypo-, meso- holo- and hyper-endemic. The 
epidemiological profile is usually determined in any given 
location by several factors including the ecosystem, 
climate, state of the environment, human behaviour, and 
vector and parasite bionomics (FMoH, 2000).  
The recent increases in malaria mortality rates in Africa 
are probably due to increasing resistance to insecticides 
and antimalarial drugs, breakdown in public-health 
infrastructure, and land-use changes-such as dam-
building, irrigation, and deforestation (Sachs and 
Malaney, 2002; WHO/UNICEF, 2003). In this review 
article, we briefly discuss the burden of falciparum 
malaria in sub-Saharan Africa and the challenges and 
opportunities for the implementation of antimalarial 
interventions within the region. 
 
 
BURDEN OF MALARIA DISEASE IN SUB-SAHARAN 
AFRICA 
 
Despite considerable progress in malarial control over 
the past decade, malaria remains one of the most 
important potentially fatal parasitic diseases in the world. 
It is a major public health problem and a negative factor 
in the socio-economic development in sub-Saharan  




















Africa. It is one of the top three killers among communi-
cable diseases, particularly in tropical Africa.  
 
Economic impact of malaria: In a World Health 
Organization (WHO) report, half of over 2400 million of 
the world’s population at risk of malaria are in Africa 
(WHO, 2000). Malaria affects the health and wealth of 
nations and individuals alike. In Africa today, malaria is 
understood to be both a disease of poverty and a cause 
of poverty (Greenwood andMutabingwa, 2002; Sachs 
and Malaney, 2002). Malaria has significant measurable 
direct and indirect costs, and has been shown to be a 
major constraint to economic development (Sacks and 
Malaney, 2002).  What this means is that the gap in 
prosperity between countries with malaria and countries 
without malaria has become wider every single year. 
Gallup and Sachs (2003) show that where malaria has 
been eliminated economic growth has increased 
substantially over the following five years, compared to 
growth in neighouring countries. Countries with intensive 
malaria lagged behind in growth by 1.3% per person per 
year compared to neighbouring countries; a 10% 
decrease in malaria incidence was associated with a 
0.3% increase in annual economic growth (Breman et al., 
2001).  
 
Morbidity and mortality associated with malaria in 
children: About 300 to 500 million clinical cases of 
malaria occur each year with 90% of these occurring in 
tropical Africa - mostly caused by P. falciparum (WHO, 
1999; Sachs and Malaney, 2002). In Africa, a visit to the 
paediatric ward or to the general outpatient department 
of most hospitals is all that is needed to convince a 
visitor that malaria remains a major cause of mortality 
and morbidity in African children. Malaria accounts for 10 
to 30% of all hospital admissions and is responsible for 
15 to 25% of all deaths of children under the age of five 
(WHO, 1999). Between the 1980s and the 1990s, 
malaria-related deaths in children doubled in many parts 
of Africa, and malaria now accounts for about a fifth of 
childhood mortality (WHO, 2003).  
 
Burden of malaria during pregnancy: Pregnant women 
are also at high risk from malaria, and malaria is 
responsible for a substantial number of maternal 
morbidity, and perinatal morbidity and mortality (WHO, 
2001). In pregnancy, the consequences of malaria are 
severe both to the mother and her unborn child. Malaria 
in pregnancy can result in a number of maternal, fetal 
and infant complications (Figure 1). Important examples 
are: severe maternal illness, hypoglycaemia, acute 
pulmonary oedema and anaemia; fetal distress, 
premature labour, intrauterine growth retardation (IUGR), 
prematurity, low birth weight infants and stillbirths 
(Bouvier et al., 1997; Brabin, 1983; Menendez, 2000; 
Philips-Howard, 1999; Schultz et al., 1995, Shulman, 
2001, and Steketee, 2001). Malaria during pregnancy 
contributes to approximately 2 to 15% of maternal 
anaemia and 8 to 14% of low birth weight in areas with 
stable malaria transmission, where prevalence during 
pregnancy ranges from 10 to 65% (Steketee et al., 
2001). Malaria contributes to an estimated 8 to 36% of 
prematurity and to an additional 13 to 70% of intrauterine 
growth retardation, depending on level of malaria risk 
and 3 to 85 of all infant deaths (Steketee et al., 1996b). 
Steketee et al (1996b) have shown that maternal malaria 
infection accounts for almost 30% of all the causes of low 
birth weight that can be prevented during pregnancy 
through antenatal intervene-tions. Maternal  parasitized  
red   blood  cells  and perivil- 
 




lous fibrin deposition were found to be associated 
independently with increased risk of premature delivery. 
Massive mononuclear intervillous inflammatory infiltration 
is an important mechanism in the pathogenesis of IUGR 
in malaria-infected placentas. Placenta malaria was 
associated with prematurity even in high transmission 
areas (Menendez et al., 2003).  
 
Malaria and HIV during pregnancy: Placenta malaria is 
more common in HIV–positive than HIV-negative women 
(Brahmbhatt, 2003). HIV infection alters patterns of 
malaria in pregnant women (van Ejik, 2003). 
Interventions to reduce malaria during pregnancy could 
potentially reduce mother-to-child transmission (MCTC) 
of HIV (Brahmbhatt, 2003). Therefore, in areas with both 
infections (malaria and HIV), all pregnant women should 
use malaria prevention (van Ejik et al., 2003).  
 
 
MALARIA INTERVENTION IN SUB-SAHARAN 
AFRICA 
 
The Global Malaria Control Strategy is a concerted effort 
meant to bring about changes in the way malaria 
problem is addressed. As a result, this strategy stresses 
the selective use of preventive measures wherever they 
can lead to sustainable results (WHO, 1993). The 
measures are aimed at halting the deteriorating effects of 
the malaria situation, minimizing the wasteful use of 
resources and contributing appropriately to the 
development of health services, intersectoral cooperation 
and community participation. The ultimate goal of malaria 
control will be to prevent mortality and reduce morbidity 
and social and economic loss through the progressive 
improvement and strengthening of local and national 
capacities (WHO, 1993; FMoH, 2000). 
Several interventions have been recommended to curb 
the rising burden of the disease in endemic regions. 
These interventions form the pillar of the global 
campaign for effective malaria intervention, particularly in 
sub-Saharan Africa. In April 25, 2000, African Heads of 
State and Government at the Abuja, Nigeria summit on 
Roll Back Malaria expressed their political will to 
vigorously pursue the interventions. The target set at the 
Summit was that by 2005 at least 60% of those at risk of 
malaria particularly pregnant women and children under 
five years of age will benefit from the most suitable 
combination of personal and community protective 
measures such as insecticide-treated mosquito nets and 
other interventions which are accessible and affordable 
to prevent infection and suffering (FMoH, 2000).  
 
Insecticide-treated bed net (ITNs): ITN is one of the 
measures recommended to curb the rising burden of the 
disease (Figure 2). It reduces human-vector contact by 
acting as a barrier to prevent vector mosquitoes bite or 





sleepers, but also killing or shortening their lifespan if 
they land on ITNs (WHO, 2001; WHO, 2000).  High 
levels of ITN coverage provide protection both to the 
individuals sleeping under them and to other community 
members (WHO 2001). Several controlled studies mainly 
from Africa have demonstrated the preventive effects of 
ITNs. Bed net use was found to have a marginal impact 
in reducing maternal malaria-associated anemia (Dolan 
et al., 1993). The incidence of anaemia at all study sites 
was significantly lower at delivery in the permethrin-
impregnated bed net (27%) and non-impregnated bed 
net (41%) than those using no net (56%).  In another 
study, the effectiveness of ITN in Kilifi district, Kenya, ITN 
had little impact on the morbidity associated with malaria 
infection in primigravidae, despite its documented 
evidence on paediatric severe malaria and mortality 
(Shulman, 1998). However, in a recent study ITN was 
found to substantially reduce childhood mortality at 
peripheral health facilities in western Kenya (Philips-
Howards, 2003). 
 
Intermittent preventive treatment (IPT): This involves 
the administration of two or three full, curative treatment 
doses of an efficacious, preferably single-dose, 
antimalarial drug (e.g. sulfadoxine/pyrimethamine) at 
predefined intervals during pregnancy, beginning in the 
second trimester after quickening. IPT can significantly 
reduce maternal anemia and low birth weight (van Eijk et 
al., 2004). Women should receive at least two doses of 
IPT, each at least one month apart, and this has been 
found to be highly effective in decreasing the proportion 
of women with placental malaria infection at delivery 
(Schultz et al., 1994; Schultz et al., 1995). A study in 
Malawi showed that with the use of 
sulphadoxine/pyrimethamine (S/P)-based IPT, led to a 
decrease placenta malaria prevalence from 31.9 to 22% 
and a decrease in prevalence of low birthweight from 
23% in women not receiving S/P to 10.3% in women 
given > or = 2 doses. There were also higher maternal 
haemoglobin concentrations (Rogerson, 2000). IPT can 
be administered under direct observation in the clinic or 
be given in the community. WHO recommends a 
schedule of four antenatal care visits, with three visits 
after quickening. The delivery of IPT with each scheduled 
visit after quickening will help ensure that a high 
proportion of women receive at least two doses (Figure 
3). 
Intermittent preventive treatment for infants (IPTi) is 
currently been tried in some malaria research areas in 
Africa. Reports have shown that sulphadoxine/pyrimeth-
amine-based IPTi given during immunization was 
effective in protecting children against malaria. The 
resultant effects will be reduced malaria morbidity and 
mortality among this patient population (Schellenberg et 
al., 2001; Verhoef et al., 2002).  
 
Case management of malaria:  Early diagnosis, prompt 
and   effective   treatment   is   one    of    the    strategies  











Figure 3. WHO recommended IPT administration schedule (Source: WHO 
Regional Office for Africa, 2004). 
*HIV infection diminishes a pregnant woman‘s ability to control Plasmodium 
falciparum infections. Women with HIV infection are thus more likely to have 
symptomatic infections and to have an increase risk for malaria-associated adverse 
birth outcomes. At least three doses of IPT are required to obtain maximum 
protection. In areas where HIV prevalence among pregnant women is > 10%, a 
third dose of IPT should be administered at the last scheduled antenatal care visit. 




developed by the World Health Organization to combat 
malaria disease, and it remains the main pillar of global 
malaria control programme (WHO, 2000). Prompt and 
adequate clinical case management of malaria results in 
early resolution of the clinical symptoms and hence 
decrease in morbidity and mortality. It also decreases 
school and work absenteeism, resulting in improved 
productivity and economic growth (Were, 2004). This 
intervention is in-line with the Abuja summit on malaria 
that stated that by year 2005, 60% of malaria episodes 
should be appropriately treated within 24 hours of onset 





Many malaria endemic countries have guidelines for 
malaria preventive measures, particularly among the 
high risk groups (under five children and pregnant 
women). However, the effectiveness of these 
interventions is being challenged by a number of factors. 
In a study by Enato and Okhamafe (2005) in two 
Nigerian rural communities, low coverage of antimalarial 
intervention during pregnancy was found, possibly due to 
poor delivery system. It has been noted that the success 
of any programme depends not only on the efficacy of 
the intervention provided under ideal and controlled 
conditions, but also on achieving optimal use by the 
target population (Fosu, 1994). The challenges faced by 
the malaria control programmes in sub-Saharan Africa 
can be classified into: delivery systems for ITNs and IPT 
for malaria prevention, malaria drug resistance and poor 
accessibility of health care facilities.  
 
Delivery system for ITNs and IPT: This is the 
development of effective means to ensure a wider 
coverage in the delivery of these interventions. The 
delivery of ITNs services is expected to ensure a wider 
net ownership and insecticide-treatment of nets on time, 
and to provide relevant information to encourage proper 
use (WHO, 2001b). The specific issues to address 
include: 
 
• Quality assurance of products delivered. 
• Gaining access to other formal and non-formal public 
and the private sector and community-based 
structures and processes in support of INT delivery. 
• Access to populations at higher risk of contracting 
malaria (e.g. under five children and pregnant 
primigravidae), focusing on those who may live in 
less accessible areas, and/or cannot afford the 
services. 
 
In a study of the impact ITNs on malaria and anaemia in 
pregnancy in Kassena-Nankara district Ghana, it was 
found that effective use varied from 42% in primigravidae  





insecticide impregnation (Brown, 2001). 
The control of malaria in pregnant African women 
applied through antenatal care has been particularly 
challenging (Steketee et al., 1996; Philips-Howard, 
1999). Antenatal care (ANC) services are traditionally 
delivered from health facilities along with other health 
promotive and preventive programmes such as 
vaccination and under five clinics. However, often the 
services suffer from problems of accessibility, 
affordability and client satisfaction. In such 
circumstances, pregnant women, when seeking health 
care during pregnancy often opt for alternative services 
provided at the community level where female relatives 
and traditional birth attendants can play a major role 
(Magnussen, 2003). For example, only 42% of pregnant 
women in Uganda attend the required four ANC visits 
and less than 40% deliver at health units 
(Ndyomuggenyi, 1998). 
The preventive and control recommendations for 
typical area of high P. falciparum transmission have 
promoted the use of antimalarial chemoprophylaxis using 
chloroquine (Steketee et al., 1996b), and use of 
sulphadoxine/pyrimethamine (S/P) as intermittent 
preventive therapy (IPT). However, the concept of using 
antimalarial drugs to prevent malaria is not wide spread 
and this leads to low compliance with usual 
chemoprophylaxis regimens (weekly chloroquine). Most 
pregnant women in high transmission areas are 
asymptomatic and are more aware and worried about 
side-effects of antimalarial drugs than about the 
deleterious effects of malaria infection on them and their 
babies (Magnussen, 2003; Enato et al., 2005). Even with 
the introduction of S/P-based IPT, a logistically simpler 
intervention than weekly chemoprophylaxis, low 
coverage and compliance remain a problem. In Malawi, 
for example, 75% of pregnant women get one dose of 
S/P but only 30% get the recommended two doses 
(Rogerson et al., 2001). 
 
Resistance to antimalarial drugs: This has been 
defined “as the ability of a parasite strain to survive 
and/or to multiply despite the administration and 
absorption of a drug given in doses equal to or higher 
than those usually recommended, but within the limits of 
tolerance of the subject.” Later modification of this 
definition required accessibility of the drug in question to 
the parasite or the infected red blood cell for the time 
duration required for its normal action (Bruce-Chwatt et 
al., 1986). 
Antimalarial drug resistance weakens the impact of 
chemotherapy malaria control in Africa thereby creating a 
difficult situation for policy makers on their choice of 
drugs for implementing the early treatment strategy as 
recommended by the WHO. Antimalarial drug resistance 
is heightened in individuals e.g. children less than 5 
years, pregnant women, non-immune immigrants to 
malarious areas, malnourished individuals and in 
patients with human immunodeficiency  virus,  who  have  










reduced immunity (Bloland, 2001). Reduced immunity 
allows the survival of a residuum of parasites that are 
able to survive treatment, and as such this may further 
increase the development, intensification and spread of 
resistant strains. Verdrager (1986, 1995) in his studies 
proposed this mechanism as a significant contributor to 
resistance in South-East Asia. 
For a very long time chloroquine was the most cost-
effective antimalarial drug in most endemic regions. 
However, following reports of its resistance to P. 
falciparum in 1960 from Colombia and subsequent report 
from south-East Asia, the spread has been tremendous 
with resistant strains appearing in most parts of the 
world. Virtually all antimalarial drugs in common use, with 
the exception of the newer agents (e.g. artemisinins), 
have shown resistance to malaria parasites. Antimalarial 
drug resistance has emerged as one of the greatest 
challenges facing malaria control today, and the pace of 
the spread is greater than the pace at which new 
antimalarial drugs are being developed for clinical use. 
The geographical distribution of resistant strains of P. 
falciparum and P. vivax to any single agent varies from 
country to country, and within a particular country from 
region to region. Thairthong (1983) has shown a single 
Plasmodium isolates to consist of heterogeneous 
populations of parasite whose sensitivity range from 
highly resistant to completely sensitive strains. Also, 
epidemiological evidences exist for varying parasite 
sensitivity to the different antimalarials drugs in any 
geographical area. Several factors can lead to the 
development, intensification and distribution of 
antimalarials drug resistance. These factors can broadly 
be classified as: factors leading to treatment failure 
(incorrect dosing regimen, non-compliance with 
medications, substandard drugs and misdiagnosis), 
human behaviour, parasite and vector biology, and drug 
pharmacokinetics (Bloland, 2001). 
 
Poor access to diagnostic and curative care: A strong 
health care delivery system would ideally provide early 
diagnosis prompt and effective treatment. However, 
access to curative and diagnostic services is limited in 
malaria-endemic countries, resulting in inappropriate 
antimalarial utilization with the resultant development and 
spread of P. falciparum strains (Bloland, 2001; Enato et 





Within the African region, opportunities abound for quick 
and adequate intervention of malaria situation in the 
continent. Such interventions will include appropriate 
application  of  old  malaria  preventive  tools  adapted  to  







       Figure 5. Countries that include arteisinin-based combination therapy in antimalarial treatment policy, as of 2004  
      (RBM,  World report 2005). 
 
 
local needs and the development and application of new 
methods (e.g. vaccines and drugs). The success in the 
development and implementation of these new tools will 
depend on a connection with scientists from endemic 
countries of Africa who have a better understanding of 
local customs and are experienced in communicating 
with the poorest people in villages of Africa (Miller et al., 
2002).   
Figure 4 shows the market mix that is involved in the 
demand supply chain for insecticide-treated bed nets. 
One approach to achieve equity while not undermining 
the long-term commercial viability will be the use of 
vouchers and coupons enabling a reduced price through 
the commercial distribution network (WHO, 2000). Also, 
some researchers working in parts of Africa in 
collaboration with their overseas partners are developing 
methods which will involve the use of community-based 
approaches in the delivery of S/P-based IPT 
(Magnussen, 2003). When successful, this approach can 
also be applied to ITNs.  
Home management of uncomplicated malaria in 
children is currently being promoted to enhance 
accessibility to good, efficacious antimalarial 
chemotherapy within the shortest possible time after 
development of fever. This current effort will depend on 
the applicability of artemisinins-based combination 
therapy (ACTs), which are safe and efficacious in most 
malaria endemic regions. Most countries in sub-Saharan 
Africa have changed their antimalarial treatment policies 
to ACTs (Figure 5).  What is required right now is to 
ensure accessibility and affordability. The growing of the 
plant, Artemisia annua, is currently being under taken in 
some east African countries. The prohibitive price of 
ACTs is as a result of the high cost of the artemisinin, 
obtained from the plant. Other means to ensure 
affordability will be through deliberated international 
subsidy by donor bodies. This approach has been 
successfully used to enhance the affordability of 
antiretroviral drugs to most poor countries of the world, 
majority of who are in Africa (Mrazek, 2002).  
 
Combination therapy: Combination therapy (CT) with 
antimalarial drugs is the simultaneous use of two or more 
blood schizontocidal drugs with independent modes of 
action and different biochemical targets in the parasite. 
The concept of combination therapy is based on the 
synergistic or additive potential of two or more drugs, to 
improve therapeutic efficacy and also delay the 
development of resistance to the individual components 
of the combination (WHO, 2001a). Current combination 
therapy can be classified into nonartemisinin-based and 
artemiasinin-based combination therapies. Artemisinin-
based combination therapies (ACTs) have been shown 
to improve treatment efficacy and also curtail drug 
resistance in South-East Asia (White, 1999; White and 
Olliaro, 1996). The rationale for the use of ACTs is based 
on the combination of the rapid schizontocidal effects of 
artemisinin with the long half life of the partner drug 
(WHO, 2001). However, major challenges of deployment 
and use of antimalarial drug combination therapies, 
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